EBE Value Proposition
EBE promotes a favourable business and regulatory environment for biopharmaceutical companies of all sizes to help them successfully research, develop and market therapies derived from biotechnology in Europe. Playing a key role in the formulation of EU healthcare policies and regulations relevant to biotech-derived medicines, EBE is considered by the EU stakeholders to be truly representative of the large, mid-sized and small biopharmaceutical companies operating in Europe. With the biological drugs market continuing to grow at a significant rate, EBE is well positioned to continue this critical advocacy role on industry’s behalf.
To help shape sound policy-making, EBE raises awareness of the products and special features of the biopharmaceutical industry and how these benefit patients and society. Our target audiences include government decision-makers, the media, patient organisations, the academic community and other opinion leaders. We closely collaborate with European Commission officials in charge of our sector, regularly organise debates hosted at the European Parliament and actively participate in the key European health policy forums and biotechnology conferences all year round.
EBE is recognised by the European stakeholders as an authoritative source of information and industry expertise. On this basis, EBE has also become a trusted partner for other industry organizations worldwide. As the impact of pharmaceutical regulation on the development, registration and manufacturing of biopharmaceutical products continues apace, industry must provide input and comment, in a timely fashion, to regulatory authorities. For the past 10 years, EBE has contributed such combined industry expertise to the development of new regulatory frameworks, guidelines and standards of relevance to biopharmaceutical companies operating in Europe.
Through dedicated working parties, EBE provides the forum required by managers from large and small companies to address the key issues they face in the current European environment. We also use our forum to actively promote the exchange of good practices fostering the development of safe, efficacious and high-quality medicines.
EBE is service-driven and results-orientated. We care about supporting the business of member companies, especially SMEs. We organise business-to-business interactions, training and members-only information exchange, with the EBE Extranet acting as central resource centre. Members can learn much through participation in working parties and from the intelligence the EBE secretariat distributes on a wide range of issues.
On the regulatory front, services to member companies have been strengthened by a series of Regulatory Seminars. The aim of the seminars is to provide an up-to-date review of a selected topic by a panel of expert speakers drawn from the European and national regulatory authorities and the industry. Additionally, EBE provides business development support services. These range from workshops and identification of new potential funding sources to networking events for business development executives of biotech companies and larger pharmaceutical corporations.